Business Wire

AZ-BLUE-YONDER

Share
Avon International Leverages Blue Yonder’s AI Capabilities To Support Its Global Demand Planning, Production and Omni-Channel Strategy

The cosmetics industry is experiencing continued growth as consumers worldwide increasingly prioritize self-care and wellness. However, this growth has also led to a more competitive landscape, and companies must make strategic choices to differentiate themselves and maintain success in this dynamic market. That is why Avon International chose Blue Yonder Platform with Cognitive Demand Planning, Enterprise Supply Planning and Control Tower solutions to create an end-to-end next generation supply chain and support the company’s strategy and vision.

Avon International is a global beauty company operating in over 40 countries across Europe and Asia Pacific. The brand Avon has been in operation for over 135 years and has a business model based on relationship selling. Millions of independent representatives offer personalised beauty advice to their customers through offline and online channels. The brand is also accessed through wholesalers, retail stores and marketplaces.

Avon International was seeking to optimize its manufacturing and distribution processes in both Europe and Asia Pacific by establishing a "Planning Hub" for centralized demand and supply planning. To streamline demand planning, respond more quickly to their dynamic market and enhance decision-making, Avon International selected Blue Yonder’s flexible SaaS supply chain solutions, based on advanced artificial intelligence (AI) and machine learning (ML) capabilities.

“Avon International is committed to transforming itself to meet the needs of its customers, Representatives and partners while staying true to its business model and values. To support this global transformation across all channels, Avon International recognized the need for a more integrated approach to demand planning. After a thorough selection process, Blue Yonder was chosen for its comprehensive solutions and innovative capabilities that met all of Avon International’s needs. With Blue Yonder’s supply chain solutions, powered by leading-edge AI and ML capabilities, Avon International will be empowered to meet the changing needs of its customers, representatives, and partners in a profitable and sustainable way,” said Maciej Kaniowski, COO, Avon International.

The need to reduce inventory across the company has made accurate forecasting and efficient demand planning a business imperative. Blue Yonder solutions’ key differentiators include not only the robustness, experience, and scalability of ML forecasting, but also the extensibility and explainability of causal factors, that for Avon include campaigns, price, promotions, catalogue position, and seasonality.

These factors train Blue Yonder’s ML models to predict future demand. Blue Yonder’s explainability and scenario composable services help planners understand causal contributions and run simulations based on changes like price or promotions, resulting in superior accuracy, greater explainability, and improved decision-making.

Once the Blue Yonder solutions are implemented, Avon International will be able to drive supply chain process simplification and achieve the following benefits:

  • Streamline operations with an integrated, end-to-end planning process for managing trends, demand, supply, inventory, and vendor collaboration.
  • Surpass forecast accuracy and achieve improved planner efficiency with the configuration of Avon’s causal factors.
  • Expand omni-channel capabilities and gain a competitive edge by forecasting and planning for all channels and offer types in one solution.
  • Improve service levels and optimize cash flow with a comprehensive forecasting and planning solution that supports a centralized planning hub.

Avon International’s manufacturing supply chain operations in Europe and Asia Pacific are managed by Avon Operations Polska (AOP) and Avon Distribution Polska (ADP), with the backbone of their activities located in Garwolin, Poland. AOP manages the largest and most technologically advanced Avon factory worldwide. Cosmetics manufactured here are distributed to approximately 40 countries on three continents.

"We are thrilled to be a part of Avon International’s supply chain digital transformation. It is an honor to work with a company that shares our same commitment to values such as inclusion, women empowerment, and equity. The Blue Yonder solutions will enable Avon International to adapt to changing market conditions and external dynamics, ensuring their supply chain remains agile, sustainable, and competitive," said Terry Turner, president, Manufacturing, Blue Yonder.

Additional Resources:

About Avon

At Avon, we believe a better world for women is a better world for all. We are the beauty brand for women embracing their power, inspiring their confidence and providing opportunities to realise their potential. Millions of independent sales Representatives across the world sell iconic Avon brands through their social networks and more than 20% of every sale helps to create better futures for women*. We stand for progress for women: we believe in listening to women’s needs, speaking out about issues that matter and creating positive change. Through Avon and the Avon Foundation, we have donated over $1.1 billion, with a focus on tackling gender violence and breast cancer. Avon is part of the Natura &Co Group.
*Learn more at www.avonworldwide.com.

About Blue Yonder

Blue Yonder is the world leader in digital supply chain transformation. Global retailers, manufacturers and logistics providers leverage Blue Yonder to optimize their supply chains from planning through fulfillment, delivery and returns. Blue Yonder’s AI-embedded, interoperable supply chain solutions are connected end-to-end via a unified platform and data cloud, enabling businesses to collaborate in real time across functions, which supports more agile decision-making, improved customer satisfaction, profitable growth, and more resilient, sustainable supply chains. Blue Yonder - Fulfill your Potential blueyonder.com

“Blue Yonder” is a trademark or registered trademark of Blue Yonder Group, Inc. Any trade, product or service name referenced in this document using the name “Blue Yonder” is a trademark and/or property of Blue Yonder Group, Inc. All other company and product names may be trademarks, registered trademarks or service marks of the companies with which they are associated.

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

View source version on businesswire.com: https://www.businesswire.com/news/home/20240702770779/en/

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com
DK

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Scoring Big With Fans: Balchem Spotlights the Power of Vitamin K2 at FC Bayern Women’s Season Opener18.9.2025 14:33:00 CEST | Press release

Balchem, a leading global manufacturer of specialty ingredients for human nutrition and health – and official partner of FC Bayern (FCB) Women’s football team - has launched its first ever direct-to-consumer initiative, showcasing the power of vitamin K2 to FCB fans. The company promoted its K2VITAL™ brand with an exhibition stand at the Allianz Arena in Munich, during the opening game of the Bundesliga (German football league) on 6 September. This initiative is part of Balchem’s latest marketing strategy, which aims to raise consumer awareness of the health benefits vitamin K2 has to offer, bridging the gap between B2B and B2C markets. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250918950889/en/ Balchem Spotlights The Power of Vitamin K2 at FC Bayern Women’s Season Opener Co-Branded K2 Health Vitamins Hit the Pitch The opening event of the season provided a unique platform for Balchem to promote K2VITAL™, a patented, typ

Vertex Announces CASGEVY® Reimbursement Agreement for the Treatment of Transfusion-Dependent Beta Thalassemia and Sickle Cell Disease in Italy18.9.2025 14:30:00 CEST | Press release

- CASGEVY is the first, and only, gene editing therapy approved for the treatment of transfusion-dependent beta thalassemia (TDT) and sickle cell disease (SCD) in Europe -- Italy has the largest population of people living with TDT in Europe- Vertex Pharmaceuticals (Nasdaq: VRTX) announced today a reimbursement agreement with the Italian Medicines Agency (AIFA) for eligible transfusion-dependent beta thalassemia (TDT) and severe sickle cell disease (SCD) patients to access the CRISPR/Cas9 gene-edited therapy, CASGEVY® (exagamglogene autotemcel). “Today is a turning point for eligible people in Italy living with transfusion-dependent beta thalassemia and sickle cell disease, two life-shortening diseases with limited treatment options,” said Ludovic Fenaux, Senior Vice President, Vertex International. “Italy has the largest TDT population in Europe, which underscores the importance of this agreement. We appreciate the collaboration with AIFA to recognize the value a one-time transformati

European DataWarehouse Appoints Nigel Batley as Executive Director of Its UK Subsidiary18.9.2025 12:41:00 CEST | Press release

European DataWarehouse Ltd. (EDW Ltd.) the UK subsidiary of European DataWarehouse GmbH, today announced the appointment of Nigel Batley as Executive Director. Mr. Batley succeeds Markus Schaber, who will retire from the role after serving as Executive Director since 2020. With nearly 40 years of experience in the financial services industry, Mr. Batley brings extensive expertise in asset-backed finance. He spent more than 30 years at HSBC, where he held senior positions including Global Head of Structured Finance, before taking on advisory and leadership roles in the securitisation market. Markus Schaber, outgoing Executive Director of EDW Ltd., will remain with the company as Senior Advisor. He commented: “It has been a privilege to lead European DataWarehouse in the UK and contribute to the development of greater transparency in European securitisation markets. I am confident that Nigel’s deep industry knowledge and leadership will strengthen EDW Ltd.’s mission and ensure we continu

Zycus Recognized as A Customers’ Choice in 2025 Gartner® Peer Insights™ “Voice of the Customer” for Source-to-Pay Suites18.9.2025 11:20:00 CEST | Press release

Zycus, a global leader in procurement and source-to-pay transformation, today announced it has been recognized as A Customers’ Choice in 2025 Gartner Peer Insights™ “Voice of the Customer”: Source-to-Pay Suites report. The Gartner Peer Insights report aggregates ratings and reviews from verified end users over an 18-month ending June 30, 2025. To qualify, vendors must have at least 20 eligible reviews and meet thresholds for capabilities and support. In the 2025 report, only eight vendors qualified, with Zycus placed in the Customers’ Choice quadrant — highlighting vendors rated above the market average for both Overall Experience and User Interest & Adoption. Recognition Backed by Customer Experience According to the report, Zycus achieved: 4.6 out of 5 Overall Rating, based on 67 peer reviews as of June 30, 2025. 95% willingness to recommend score – reflecting customer trust and satisfaction. Ratings across Product Capabilities, Sales Experience, Deployment, and Support, each above 4

Neumirna Therapeutics Appoints Ellen K. Donnelly as Chief Executive Officer18.9.2025 11:00:00 CEST | Press release

Neumirna Therapeutics, a biotechnology company developing RNA-based therapies for neurological diseases, today announced the appointment of Ellen K. Donnelly, Ph.D. as Chief Executive Officer. Ellen brings more than 20 years of leadership in neuroscience and rare diseases, spanning both global pharmaceutical companies and innovative biotech firms. She joins Neumirna from her role as CEO of Abliva AB, recently acquired by Pharming Group, and has previously led Modus Therapeutics and Souvien Therapeutics. Earlier in her career, Ellen spent nearly a decade at Pfizer Inc., where she held leadership roles in neuroscience research, clinical operations, portfolio management, and strategy. She holds a Ph.D. in Pharmacology & Neuroscience from Yale University. "Ellen combines scientific expertise with proven leadership in both biotech and pharma," said Luis Pareras, Chairman of the Board at Neumirna. "The Board is confident that under her guidance, Neumirna will continue to translate our innova

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye